Management of the patent ductus arteriosus in preterm infants.
Cyclo-oxygenase inhibitors (COX-I)
Hemodynamically significant (hs)-PDA
Patent ductus arteriosus
Preterm infants
Procedural PDA closure
Journal
Paediatrics & child health
ISSN: 1205-7088
Titre abrégé: Paediatr Child Health
Pays: England
ID NLM: 9815960
Informations de publication
Date de publication:
Mar 2022
Mar 2022
Historique:
received:
26
11
2020
accepted:
07
07
2021
entrez:
11
3
2022
pubmed:
12
3
2022
medline:
12
3
2022
Statut:
epublish
Résumé
Management of the patent ductus arteriosus (PDA) is one of the most contentious topics in the care of preterm infants. PDA management can be broadly divided into prophylactic and symptomatic therapy. Prophylaxis with intravenous indomethacin in extremely low birth weight infants may reduce severe intraventricular hemorrhage. Echocardiography should be routinely used to confirm the presence of a PDA before considering symptomatic therapy. A symptomatic PDA can be managed conservatively, using pharmacotherapy or with procedural closure. Ibuprofen should be considered as the pharmacotherapy of choice for a symptomatic PDA. High-dose ibuprofen may be preferable, especially for preterm infants beyond the first 3 to 5 days of age. If pharmacotherapy fails (after two courses) or is contraindicated, procedural closure may be considered for infants with a persistent PDA with significant clinical symptoms in addition to echocardiographic signs of a large PDA shunt volume and pulmonary over-circulation.
Identifiants
pubmed: 35273674
doi: 10.1093/pch/pxab085
pii: pxab085
pmc: PMC8900701
doi:
Types de publication
Journal Article
Review
Langues
eng
eng
Pagination
63-64Informations de copyright
© Canadian Paediatric Society 2022. Published by Oxford University Press on behalf of the Canadian Paediatric Society. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.